Eide, Christopher A.
Kurtz, Stephen E. http://orcid.org/0000-0003-4762-389X
Kaempf, Andy
Long, Nicola
Agarwal, Anupriya
Tognon, Cristina E.
Mori, Motomi
Druker, Brian J. http://orcid.org/0000-0001-8331-8206
Chang, Bill H. http://orcid.org/0000-0003-3783-1820
Danilov, Alexey V. http://orcid.org/0000-0003-4461-0970
Tyner, Jeffrey W.
Funding for this research was provided by:
National Cancer Institute
Article History
Received: 7 June 2019
Revised: 7 February 2020
Accepted: 12 February 2020
First Online: 24 February 2020
Compliance with ethical standards
:
: This manuscript contains original research, has not been previously published, and is not under consideration for publication elsewhere. AVD has received commercial research grants from Gilead Sciences, Verastem, Takeda, AstraZeneca, and Verastem Oncology, and is a consultant/advisory board member for AbbVie, AstraZeneca, Genentech, Verastem Oncology, Seattle Genetics, TG Therapeutics, Curis, Celgene, Teva Oncology, and Gilead Sciences. BJD serves on the board of directors of Amgen, Burroughs Wellcome Fund, and CureOne; reports receiving other commercial research support from Novartis, Bristol-Myers Squibb, and Pfizer (institutional funding—PI or coinvestigator on clinical trials funded via contract with OHSU); has ownership interest (including stock, patents, etc.) in Amgen, Blueprint Medicines, MolecularMD (inactive—acquired by ICON Laboratories), GRAIL, Patent 6958335 (exclusively licensed to Novartis), Henry Stewart Talks, Merck via Dana-Farber Cancer Institute (royalty payments); is a consultant/advisory board member for Aileron Therapeutics, ALLCRON, Third Coast Therapeutics, Monojul (inactive), Baxalta (inactive), CTI Biopharma (inactive), Aptose, Beta Cat, Blueprint Medicines, Celgene, Cepheid, GRAIL (former), Gilead (former), and Patient True Talk; and is an uncompensated joint steering committee member for Beat AML LLC. JWT has received commercial research grants from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Petra, Seattle Genetics, Syros, and Takeda; has received honoraria from the speakers bureaus of Therapeutic Advances in Childhood Leukemia and Hermedicus—Acute Leukemia Forum. No potential conflicts of interest were disclosed by the other authors.